Patient-derived organoids reveal strain-specific efficacy of engineered bacteria in colorectal cancer

Background Engineered bacteria are emerging as promising vectors for drug delivery and immune modulation within solid tumors, yet standardized preclinical models for evaluating strain-specific efficacy, tumor selectivity, and host interactions remain lacking. Patient-derived organoids recapitulate the architecture and genetic fidelity of primary tissue, offering a physiologically relevant alternative to conventional cell lines for testing microbial cancer therapeutics. Methods We established a co-culture platform pairing patient-derived colorectal cancer and matched normal mucosa organoids with two clinically relevant engineered bacterial strains: attenuated Salmonella typhimurium and Escherichia coli Nissle 1917. Colonization dynamics were quantified by colony-forming unit assay and time-lapse fluorescence imaging. Strain-specific host responses were characterized through transcriptomic profiling, histological staining, quantitative morphological analysis, and secondary organoid-forming assays across two genotypically distinct patient lines. Results Here we show that both strains preferentially colonize colorectal cancer organoids over matched normal mucosa. Salmonella achieves markedly higher colonization efficiency and exerts a greater impact on host transcriptional and morphological responses than E. coli Nissle 1917. Comprehensive phenotypic profiling reveals strain-specific disruption patterns, and cancer organoid responses are both strain- and patient genotype-dependent. Conclusions Patient-derived organoid co-cultures serve as a scalable and informative platform for preclinical chassis selection in microbial cancer therapeutics, capturing interpatient variability in a manner analogous to patient-derived organoid-based drug screening. These findings support attenuated Salmonella as a particularly effective chassis for future engineered bacterial therapies targeting colorectal cancer.

Authors

Institutions

Publication Details

Journal
Communications Medicine
Published
2026-11-18
DOI
https://doi.org/10.1038/s43856-026-01992-x
Primary Topic
Bacterial Cancer Therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Patient-derived organoids reveal strain-specific efficacy of engineered bacteria in colorectal cancer

Daniel L. Worthley, Laura Vrbanac, Kate R. Barratt, Susan Lesley Woods et al.
5 links
Communications Medicine
Bacterial Cancer Therapy
article

Patient-derived organoids reveal strain-specific efficacy of engineered bacteria in colorectal cancer

Daniel L. Worthley, Laura Vrbanac, Kate R. Barratt, Susan Lesley Woods, Josephine A. Wright, Jeff Hasty, Paige Steppe, Katherine O’Connor, Deniz Erkok
article en

Abstract

Background Engineered bacteria are emerging as promising vectors for drug delivery and immune modulation within solid tumors, yet standardized preclinical models for evaluating strain-specific efficacy, tumor selectivity, and host interactions remain lacking. Patient-derived organoids recapitulate the architecture and genetic fidelity of primary tissue, offering a physiologically relevant alternative to conventional cell lines for testing microbial cancer therapeutics. Methods We established a co-culture platform pairing patient-derived colorectal cancer and matched normal mucosa organoids with two clinically relevant engineered bacterial strains: attenuated Salmonella typhimurium and Escherichia coli Nissle 1917. Colonization dynamics were quantified by colony-forming unit assay and time-lapse fluorescence imaging. Strain-specific host responses were characterized through transcriptomic profiling, histological staining, quantitative morphological analysis, and secondary organoid-forming assays across two genotypically distinct patient lines. Results Here we show that both strains preferentially colonize colorectal cancer organoids over matched normal mucosa. Salmonella achieves markedly higher colonization efficiency and exerts a greater impact on host transcriptional and morphological responses than E. coli Nissle 1917. Comprehensive phenotypic profiling reveals strain-specific disruption patterns, and cancer organoid responses are both strain- and patient genotype-dependent. Conclusions Patient-derived organoid co-cultures serve as a scalable and informative platform for preclinical chassis selection in microbial cancer therapeutics, capturing interpatient variability in a manner analogous to patient-derived organoid-based drug screening. These findings support attenuated Salmonella as a particularly effective chassis for future engineered bacterial therapies targeting colorectal cancer.

Communications Medicine
University of California San Diego (US), South Australian Health and Medical Research Institute (AU)
National Science Foundation
Good health and well-being
Bacterial Cancer Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon